CDKN2A and non-small cell lung carcinoma: Previous studies have revealed that promoter methylation of the p16INK4a gene occurs more frequently in NSCLC patients before treatment and in patients with leukopenia, suggesting that promoter methylation of the p16INK4a gene may be associated with late clinical stage [30].